WO2009147476A1 - Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation - Google Patents

Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation Download PDF

Info

Publication number
WO2009147476A1
WO2009147476A1 PCT/IB2009/000186 IB2009000186W WO2009147476A1 WO 2009147476 A1 WO2009147476 A1 WO 2009147476A1 IB 2009000186 W IB2009000186 W IB 2009000186W WO 2009147476 A1 WO2009147476 A1 WO 2009147476A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
compound according
compound
dihydro
pharmaceutically acceptable
Prior art date
Application number
PCT/IB2009/000186
Other languages
French (fr)
Inventor
Lal Jabaris Sobhana George Sugin
Gupta Rajesh Vidyawant
Manne Narendra Kumar
Sreelatha Vanjivaka
Pal Manojit
Singh Santosh Kumar
Havale Shrikant Hanumamtappa
Kodimuthali Arumugam
Venkata Laxmi Kishore Parsa
Original Assignee
Matrix Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrix Laboratories Ltd. filed Critical Matrix Laboratories Ltd.
Publication of WO2009147476A1 publication Critical patent/WO2009147476A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Definitions

  • Novel PDE Inhibitors pharmaceutical compositions containing them and processes for their preparation
  • the present invention relates to novel heterocyclic compounds that may be useful as phosphodiesterase inhibitors (PDEs), in particular phosphodiesterase type 4 inhibitors represented by general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their bioisosters, their diastereomers, their polymorphs, their enantiomers, their appropriate N-oxides, their pharmaceutically acceptable salts, their pharmaceutically acceptable hydrates, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them and their use in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor(TNF- ⁇ ).
  • PDEs phosphodiesterase inhibitors
  • I phosphodiesterase type 4 inhibitors represented by general formula (I)
  • their derivatives their analogs, their tautomeric forms, their stereoisomers, their bioisosters, their diastereomers, their polymorphs, their enantiomers, their appropriate N-oxides, their pharmaceutically acceptable salts
  • Bronchial asthma is a complex multifactorial disease characterized by hyperactivity of the respiratory tract to external stimuli.
  • Airway inflammation leads to a number of severe lung diseases including Asthma and Chronic Obstructive Pulmonary Diseases (COPD, also known as Chronic Obstructive Airway Disease, Chronic Obstructive lung Disease or chronic airflow limitation and chronic airflow obstruction.).
  • COPD Chronic Obstructive Pulmonary Diseases
  • the airflow limitation is usually progressive and associated with abnormal inflammatory response of the lungs to noxious particles or gases.
  • cyclic nucleotides mainly cAMP and cGMP
  • ACs adenylyl cyclases
  • GCs guanylate cyclases
  • PDEs Phosphodiesterases
  • these PDEs fall into three categories like those that are specific to (i) cAMP, (ii) cGMP and (iii) those that act on both cAMP and cGMP. These 11 groups of PDEs are classified according to their nucleotide selectivity. PDE4 has 4 isoforms and in all these isoforms upstream conserved regions (UCRs) are present which appear to modulate dimerisation and may bind to signaling molecules such as lipids. At least 18 different splice variants of the four PDE4 isoforms exist. Because of the critical role of cAMP in mediating cytokine responses, cAMP specific PDE (PDE-4) plays an important role in the progression of inflammatory diseases.
  • UCRs upstream conserved regions
  • PDE4 enzymes as their primary cAMP specific PDE.
  • inflammatory diseases that are implicated by these cellular mediators are asthma, chronic obstructive pulmonary diseases (COPD), rheumatoid arthritis, inflammatory bowel disease, crohn's disease and multiple sclerosis. Consequently the development of PDE4 inhibitors as therapeutic agents for these diseases has been a major pharmaceutical focus.
  • PDE4 indirectly controls the degree of bronchodilation.
  • cAMP is a negative regulator of the primary activating pathways such as cytokine release by T-cells.
  • inhibition of PDE4 enzyme increases levels of cAMP and Cyclic AMP modulates the activity of most of the cells that contribute to the pathophysiology of allergic asthma. Elevation of cAMP would produce beneficial effects, some of which include apart from airway smooth muscle relaxation, inhibition of mast cell mediator release, suppression of neutrophil degranulation, inhibition of basophil degranulation and inhibition of monocyte and macrophage activation.
  • the connection between PDE4 activity and cognition has been speculated ever since the discovery that the cAMP-regulating dunce gene of the fruit fly encodes a PDE4 homo ⁇ ogae(Nature, 1981, 289,5793, 79-1; J. mol. UoI, 1991,222, 3, 553-565).
  • Patent application WO93/19749 claims the compounds shown below which are useful for allergy and inflammatory states. - A -
  • Patent US5811455 claims the compounds of formulae AA and BB
  • PDE4 As described above, as regulation of intracellular signaling is coordinated by PDE4, It has become a validated target for the development of therapeutics for inflammatory diseases such as asthma and COPD. PDE4 also has been shown to be a potential target for depression, memory enhancement, cardiovascular disease and osteogenesis.
  • Ring A is selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl
  • Z is selected from C(O), NR 1 , S(O) 1n , C(O)NR 1 , NR ⁇ CO), CR 2 R 3 ,
  • R 1 is selected from hydrogen or substituted or unsubstituted alkyl
  • R 2 and R 3 are independently selected from hydrogen, C 1 -C 6 straight or branched alkyl, C 2 -C 6 straight or branched alkenyl, alkylamino, alkyl halo, alkyl hydroxy, acyl, alkoxy; or
  • Ring B is selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl m represents an integer ranging from O, 1 or 2;
  • the present invention relates to compounds represented by general formula (II)
  • Hy represents substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl;
  • the present invention relates to compounds represented by general formula (III)
  • Hy represents substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl
  • the present invention relates to compounds represented by general formula (III) wherein Z is C(O) and Hy is as defined above.
  • the present invention relates to compounds represented by general formula (III) wherein Z is NR 1 and Hy is as defined above. In yet another embodiment, the present invention relates to compounds represented by general formula (III) wherein Z is S(O) n ,, Hy and m are as defined above. In yet another embodiment, the present invention relates to compounds represented by general formula (III) wherein Z is CR R , Hy and m are as defined above
  • the present invention relates to compounds represented by general formula (I) wherein ring A represents but is not limited to substituted or unsubstituted moieties selected from
  • X is selected from hydrogen, hydroxyl, halo, substituted or unsubstituted amino, nitro, cyano, substituted or unsubstituted alkyl, haloalkyl, haloalkyloxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkoxy, amido, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heteroaryl, NR 1 S(O) n )R 1 , R 1 C(O)R 1 , R 1 OC(O)R 1 , -SR 1 , - SOR 1 , COOR 1 , -NR 2 R 3 , -NR 1 C(O)R 1 ;
  • R 1 , R 2 and R 3 are as defined above; n represents an integer ranging from O, 1, 2 or 3;
  • the present invention relates to compounds represented by general formula (I) wherein ring B represents but is not limited to substituted or unsubstituted moieties selected from
  • the compounds of the present invention may inhibit or regulate the TNF alpha production and are useful in the treatment of allergic and inflammatory diseases including asthma, allergic conditions, allergic conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, diabetes, Crohn's disease, allergic rhinitis, endotoxic shock and adult respiratory distress syndrome.
  • allergic and inflammatory diseases including asthma, allergic conditions, allergic conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, diabetes, Crohn's disease, allergic rhinitis, endotoxic shock and adult respiratory distress syndrome.
  • COPD chronic obstructive pulmonary disease
  • alkyl refers to a straight or branched chain saturated aliphatic hydrocarbon that may be substituted or unsubstituted.
  • alkyl include but are not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, isobutyl and the like.
  • alkenyl used herein, either alone or in combination with other radicals, denotes a straight or branched C 2 -C 6 aliphatic hydrocarbon chain containing one or more carbon to carbon double bonds that may be optionally substituted with multiple degrees of substitution being allowed.
  • alkenyl includes dienes and trienes of straight and branched chains and are selected form Vinyl allyl, 2- butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3hexenyl, 4- hexenyl, 5-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6- heptenyl.
  • alkynyl used herein, either alone or in combination with other radicals, denotes a straight or branched chain aliphatic hydrocarbon containing two to eight carbons with one or more triple bonds which may be substituted or unsubstituted.
  • alkynyl includes di-and tri-ynes, such as ethynyl, 1- propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl,l-pentynyl, 2-pentynyl, 3- pentynyl, 4-pentynyl, 1-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, and the like.
  • acyl refers to the group-C(O)R d where R d is Alkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl each as herein defined and examples of which include acetoyl, propanoyl, butanoyl, iso-butanoyl, pentanoyl, benzoyl and the like, which may be substituted or unsubstituted.
  • Alkoxy refers to a group -OR C where R c is alkyl as herein defined. Representative examples include but are not limited to methoxy, ethoxy and like.
  • Alkylamino refers to the group — N(R C ) 2 where one R c is alkyl and the other R c independently is H or alkyl as herein defined.
  • Alkylhalo refers to the group 'R c -halogen' where R 0 is alkyl defined as above and halogen is selected from Fluorine, Chlorine, Bromine and Iodine and it can be haloalkyl, dihaloalkyl or trihaloalkyl or polyhaloalkyl like methylene chloride,CF 3 ,CHF 2 ,CF 2 -CF 3 etc.
  • Halogen refers to Fluorine, Chlorine, Bromine or Iodine.
  • Alkylhydroxy or hydroxyalkyl refer to the group R 0 OH where R c is alkyl as herein defined and the representative examples include but are not limited to hydroxy methyl, hydroxy ethyl, hydroxy propyl and like.
  • Aryl refers to optionally substituted aromatic ring system having the carbon atoms in the range of five to ten carbon atoms and they may be monocyclic, bicyclic or polycyclic and unsaturated or partially saturated and one or more carbons may optionally be replaced by one or more heteroatoms selected from N, O and S.
  • exemplary aryl groups include phenyl, naphthyl, indanyl, biphenyl and like.
  • Aminosulfonyl refers to -NH-SO 2 -; “Carboxy” refers to -COO-; “Carbamoyl” refers to the group -C(O)NH 2 ; “Sulfonyl” Refer to the group -S(O) 2 -; “Sulfinyl” Refer to the group -S(O)-
  • cycloalkyl used herein, either alone or in combination with other radicals, denotes mono, bicyclic or polycyclic saturated, partially saturated hydrocarbon ring system of about 3 to 12 carbon atoms which may be substituted or unsubstituted.
  • exemplary "cycloalkyl” groups include but are not limited to cyclopopyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, perhydronapthyl, adamantyl, noradamantyl or spirobicyclic groups such as spiro (4,4)non-2-yl.
  • cycloalkylalkyl refers to a cycloalkyl ring containing 3 to 12 carbon atoms directly attached to an alkyl group which is then attached to the main structure at any carbon atom in the alkyl group that results in a stable structure such as cyclopropylmethyl, cyclobutylmethyl and the like.
  • Heteroaryl refers to monocyclic aromatic ring systems or fused bicyclic aromatic ring systems comprising two or more aromatic rings preferably two to three ring systems. These heteroaryl rings contain one or more nitrogen, sulfur and or oxygen atoms where N-oxides sulfur oxides and dioxides are permissible heteroatom substitutions.
  • the term includes ring(s) optionally substituted with halogens, nitro, amino, alkoxy, alkyl sulfonyl amino, alkylcarbonylamino, carboxy, alkyl carbonoyl, hydroxy, and alkyl.
  • heteroaryl groups include furan, thiophene, pyrrole, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, isoxazole, oxadiazole, thiadiazole, isothiazole, pyridine, pyridazine, pyrazine, pyrimidine, quinoline, isoquinoline, benzofuran, benzothiophene, indole, indazole, chromanyl, iso chromanyl and the like.
  • Heterocyclyl refers to a stable 3 to 15 membered ring that is either saturated or has one or more degrees of unsaturation or unsaturated. These heterocyclic rings contain one or more heteroatoms selected from the group consisting of nitrogen sulfur and/or oxygen atoms where N-oxides, sulfur oxides and dioxides are permissible heteroatom substitutions. Such a ring may be optionally fused to one or more of another heterocyclic ring(s), aryl ring(s) or cycloalkyl ring(s).
  • Examples of such groups may be selected from the group comprising azetidinyl, acridinyl, pyrazolyl, imidazolyl, triazolyl, pyrrolyl, thiophenyl, thiazolyl, oxazolyl, isoxazolyl, furanyl, pyrazinyl, tetrahydroisoquinolinyl, piperidinyl, piperazinyl, morpholinyl, thiomorphonilyl, pyridazinyl, indolyl, isoindolyl, quinolinyl, chromanyl and the like.
  • Heterocyclylalkyl refers to a heterocyclic ring radical defined above directly bonded to an alkyl group.
  • the heterocyclylalkyl radical may be attached to the main structure at carbon atom in the alkyl group that results in the creation of a stable structure.
  • R 6 and R 7 together along with the nitrogen they are attached with, form a 4 to 8 membered ring which can be substituted or unsubstituted.
  • the substituents in the aforementioned "substituted” groups cannot be further substituted.
  • the substituent on “substituted alkyl” is "substituted aryl”
  • the substituent on “substituted aryl” cannot be "substituted alkenyl"
  • Stepoisomers refer to certain compounds described herein containing one or more chiral centres or may otherwise be capable of existing as multiple stereoisomers. Scope of the present invention includes pure stereoisomers as well as mixtures of stereoisomers such as purified enantiomers/diastereomers or enantiomerically/diastereomerically enriched mixtures.
  • Bioisosteres refers to compounds or groups that possess near molecular shapes and volumes, approximately the same distribution of electrons and which exhibit similar physical properties such as hydrophobicity. Bioisostereic compounds affect the same biochemically associated systems as agonist or antagonists and thereby produce biological properties that are related to each other.
  • “Pharmaceutically acceptable salts” forming part of this invention include salts derived from inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, Al, Mn; salts of organic bases such as N,N'-diacetylethylenediamine, 2- dimethylaminoethanol, isopropylamine, morpholine, piperazine, piperidine, procaine, diethylamine, triethylamine, trimethylamine, tripropylamine, tromethamine, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, pyrimidine, spermidine, and the like; chiral bases like alkylphenylamine, glycinol, phenyl glycinol and the like, salts of natural amino acids such as glycine
  • Salts may include acid addition salts where appropriate which are sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, methanesulfonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates and the like.
  • “Pharmaceutically acceptable solvates” may be hydrates or comprising other solvents of crystallization such as alcohols.
  • Compounds of the invention or “present invention” refers to the compounds of the present invention represented by general formula (I) as here in defined, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their bioisosters, their diastereomers, their polymorphs, their enantiomers, their appropriate N-oxides, their pharmaceutically acceptable salts, their pharmaceutically acceptable hydrates, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.
  • the compounds of the present invention may inhibit or regulate the TNF alpha production and are useful in the treatment of allergic and inflammatory diseases including asthma, inflammatory diseases, allergic conditions, allergic conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, diabetes, Crohn's disease, allergic rhinitis, endotoxic shock and adult respiratory distress syndrome.
  • allergic and inflammatory diseases including asthma, inflammatory diseases, allergic conditions, allergic conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, diabetes, Crohn's disease, allergic rhinitis, endotoxic shock and adult respiratory distress syndrome.
  • COPD chronic obstructive pulmonary disease
  • Another embodiment of the present invention is a method of treating an inflammatory disease, disorder or condition associated with undesirable inflammatory immune response or a disease or condition induced by or associated with an excessive secretion of TNF- ⁇ and PDE-4 in humans.
  • the method includes administering to the human a therapeutically effective amount of a compound according to the general formula (I).
  • Method of treating includes preventing or delaying the appearance of clinical symptoms, inhibiting the state disorder or condition, relieving the disease causing regression of the disease.
  • the compound of general formula aa (wherein ring A and X are as defined in the specification) is oxidized using suitable oxidizing agents such as potassium permanganate, sodium chlorite, potassium dichromate, potassium chromate, pyridinium dichlorochromate, pyridinium chlorochromate, Jone's reagent (solution of chromium trioxide in concentrated sulfuric acid) and the like in the presence of suitable solvents such as acetone, acetone-water, sulfamic acid, glacial acetic acid, water, DCM, chloroform, EDC and the like to form the compound of general formula ab.
  • suitable oxidizing agents such as potassium permanganate, sodium chlorite, potassium dichromate, potassium chromate, pyridinium dichlorochromate, pyridinium chlorochromate, Jone's reagent (solution of chromium trioxide in concentrated sulfuric acid) and the like in the presence of suitable solvents such as acetone, acetone
  • the compound of general formula ab is then converted to either acid chloride or ester using suitable chlorinating agents such as thionyl chloride, phosphorus oxychloride, phosphorus trichloride or suitable reagents such as DCC/p- Nitrophenol in the presence of suitable solvents such as benzene, dimethylformide (DMF), tetrahydrofuran (THF), ethyl acetate, dichloromethane, chloroform and the like.
  • suitable chlorinating agents such as thionyl chloride, phosphorus oxychloride, phosphorus trichloride or suitable reagents such as DCC/p- Nitrophenol in the presence of suitable solvents such as benzene, dimethylformide (DMF), tetrahydrofuran (THF), ethyl acetate, dichloromethane, chloroform and the like.
  • suitable chlorinating agents such as thionyl chloride, phosphorus oxychloride, phospho
  • the acid chloride or ester thus formed is then reacted with suitable substituted or unsubstituted group represented by ring B in presence of suitable bases such as N,N-diisopropylethylamine (DIPEA), triethylamine (TEA), sodium methoxide, sodium hydride, potassium tertiary.butoxide, sodium hydroxide and the like in the presence of suitable solvents such as tetrahydrofuran, dimethylformamide (DMF), acetonitrile, water and the like to obtain the compound of general formula 1.
  • DIPEA N,N-diisopropylethylamine
  • TEA triethylamine
  • suitable solvents such as tetrahydrofuran, dimethylformamide (DMF), acetonitrile, water and the like to obtain the compound of general formula 1.
  • compound of general formula ab can be converted to compound of general formula 1 via mixed anhydride method using suitable reagent such as alkyl chloroformate or aryl chloroformate in the presence of suitable solvents such as tetrahydrofuran (THF), dioxane, chloroform, ethylene dichloride (EDC), ethyl acetate and the like.
  • suitable reagent such as alkyl chloroformate or aryl chloroformate
  • suitable solvents such as tetrahydrofuran (THF), dioxane, chloroform, ethylene dichloride (EDC), ethyl acetate and the like.
  • the compound of general formula ab is converted to compound of general formula ac using coupling reagent such as l-ethyl-(3,3'- dimethylaminopropyl)-carbodiimide (EDCI), l,l'-carbonyldiimidazole (CDI), N,N'- dicylohexylcarbodiimide (DCC), 1- hydroxyl-benzotriazole (HOBt) and the like tetrahydrofuran, dichloromethane, chloroform, ethyl acetate and the like.
  • coupling reagent such as l-ethyl-(3,3'- dimethylaminopropyl)-carbodiimide (EDCI), l,l'-carbonyldiimidazole (CDI), N,N'- dicylohexylcarbodiimide (DCC), 1- hydroxyl-benzotriazole (HOBt) and the like tetrahydro
  • stereoisomers of the compounds forming part of this invention may be prepared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomer form or by resolving the mixture of stereoisomers by conventional methods.
  • Some of the preferred methods include use of microbial resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, lactic acid, and the like wherever applicable or chiral bases such as brucine, cinchona alkaloids and their derivatives and the like.
  • Different polymorphs of a compound of general formula (I) of present invention may be prepared by crystallization of the compound of formula (I) under different conditions .
  • crystallization at different temperature ranges For example making use of commonly used solvents or their mixtures for recrystallization, crystallization at different temperature ranges, different cooling techniques like very fast to very slow cooling during crystallization procedure, by exposing to room temp, by heating or melting the compound followed by gradual cooling and the like.
  • the presence of polymorphs may be determined by one or more methods like solid probe NMR spectroscopy, DSC, TGA, Powder X- Ray diffraction and IR.
  • the present invention also provides pharmaceutical compositions containing the compounds of invention as defined above, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their bioisosters, their polymorphs ,their enantiomers, their diastereomers, their pharmaceutically acceptable salts or their pharmaceutically acceptable solvates in combination with the suitable pharmaceutically acceptable carriers, diluents.
  • the pharmaceutical compositions according to the present invention are useful for the treatment of allergic and inflammatory diseases including asthma, inflammatory diseases, allergic conditions, allergic conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, diabetes, Crohn's disease, allergic rhinitis, endotoxic shock and adult respiratory distress syndrome and related diseases.
  • the pharmaceutical composition may be tablets, capsules, powders, syrups, solutions, suspensions, sprays and like and may contain flavorants, sweeteners etc., in a suitable solid or liquid carriers or diluents or in a suitable sterile media to form injectable solutions or suspensions.
  • any reactive group in the substrate molecule may be protected according to any conventional procedure known in the prior art.
  • Suitable protecting groups comprise N-Boc, N-Cbz, N-Fmoc, alkyl, benzophenoneimine for protection of amino group, acetal protection for aldehyde, ketal protection for ketone.
  • the invention also encompasses prodrugs of compounds of the invention, which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances, In general, such prodrugs will be functional derivatives of compounds of invention, which are readily convertible in vivo into compounds of the invention.
  • the invention also encompasses the active metabolites of the compounds of the present invention of general formula (I).
  • Procedure Prepared according to the procedure reported in US 2007/0105855. Procedure: Prepared according to the procedure reported in WO 2008/005955.
  • Step 1 Preparation of (2,3-Dihydro-pyrrolo[3, 2-c]pyridin-l-yI)-(4-methoxy-8- nitro-dibenzofuran-l-yl)-methanone
  • Step 1 Preparation of (2, 3-Dihydro-pyrrolo [3, 2-c]pyridin-l-yl)-(l-methoxy-9- methyl-6-nitro-9H-carbazol-4-yl)-methanone
  • the crude acid chloride was suspended in tetrahydrofuran (15 ml) and cooled to 0 0 C and added N, N-diisopropyl-N-ethyl amine (0.35 ml) followed by 2, 3-Dihydro-lH- pyrrolo[3,2-c]pyridine (192 mg, 1.59 mmol).
  • the reaction mass was stirred overnight at room temperature.
  • the reaction mass was concentrated under vacuum completely and then water was added, stirred for about one hour.
  • the precipitated solid was filtered, washed with water and dried under vacuum to afford the titled compound (350 mg, 65% yield) as an off-white solid.
  • Step 2 N-[5-(2, 3-Dihydro-pyrrolo[3,2-c]pyridine-l-carbonyl)-8-methoxy-9- methy l-9H-carbazol-3-yl] -methanesulf onamide
  • Step 1 2, 3-Dihydro-pyrroIo [3, 2-c]pyridine-l-carboxyIic acid tert-butyl ester
  • Step 5 (7-Bromo-2, 3-dihydro-pyrrolo [3, 2-c]pyridin-l-yl)-(4-difluoromethoxy- 8-nitro-dibenzofuran-l-yl)-methanone

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel heterocyclic compounds of general formula (I), which are phosphodiesterase inhibitors (PDEs), in particular phosphodiesterase type 4 inhibitors, pharmaceutical compositions containing them, and processes for their preparation. These novel PDEs are useful in treating allergic and inflammatory diseases (such as asthma, COPD, allergic rhinitis, allergic conjunctivitis, respiratory distress syndrome, chronic bronchitis, nephritis, rheumatoid spondylitis, osteoarthritis, atopic dermatitis, eosinophilic granuloma, psoriasis, rheumatoid septic shock, ulcerative colitis, multiple sclerosis, chronic inflammation, Crohn's syndrome and central nervous system(CNS) disorders) and for inhibiting the production of Tumor Necrosis Factor(TNF-α).

Description

MATRIX LABORATORIES LIMITED Hamburg, 26 January 2009 Our reference: M 2080 / WI
Matrix Laboratories Limited
Plot No. 34A, ANRICH Industrial Estate, 502 325 BoUaram, Jinnaram Mandal -, India
Novel PDE Inhibitors, pharmaceutical compositions containing them and processes for their preparation
This application claims priority to Indian patent application No. 1324/CHE/2008 filed on June 02, 2008, the contents of which are incorporated by reference in their entirety.
Field of invention
The present invention relates to novel heterocyclic compounds that may be useful as phosphodiesterase inhibitors (PDEs), in particular phosphodiesterase type 4 inhibitors represented by general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their bioisosters, their diastereomers, their polymorphs, their enantiomers, their appropriate N-oxides, their pharmaceutically acceptable salts, their pharmaceutically acceptable hydrates, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them and their use in treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor(TNF-α). Background of the invention
Bronchial asthma is a complex multifactorial disease characterized by hyperactivity of the respiratory tract to external stimuli. Airway inflammation leads to a number of severe lung diseases including Asthma and Chronic Obstructive Pulmonary Diseases (COPD, also known as Chronic Obstructive Airway Disease, Chronic Obstructive lung Disease or chronic airflow limitation and chronic airflow obstruction.). The airflow limitation is usually progressive and associated with abnormal inflammatory response of the lungs to noxious particles or gases.
Many biological responses are mediated by levels of cyclic nucleotides, mainly cAMP and cGMP, which in turn are synthesized by adenylyl cyclases (ACs) and guanylate cyclases (GCs). To regulate levels of cAMP and cGMP, all cells have Phosphodiesterases (PDEs) that hydrolyze c AMP and cGMP to 5 ' -AMP and 5 ' - GMP. In humans there are 21 different PDE isoforms that are classified into 11 different groups. Basically, these PDEs fall into three categories like those that are specific to (i) cAMP, (ii) cGMP and (iii) those that act on both cAMP and cGMP. These 11 groups of PDEs are classified according to their nucleotide selectivity. PDE4 has 4 isoforms and in all these isoforms upstream conserved regions (UCRs) are present which appear to modulate dimerisation and may bind to signaling molecules such as lipids. At least 18 different splice variants of the four PDE4 isoforms exist. Because of the critical role of cAMP in mediating cytokine responses, cAMP specific PDE (PDE-4) plays an important role in the progression of inflammatory diseases. Many of the mediators of inflammatory response such as T cells, B cells, monocytes, neutrophils, eosinophils and macrophages have PDE4 enzymes as their primary cAMP specific PDE. Among the inflammatory diseases that are implicated by these cellular mediators are asthma, chronic obstructive pulmonary diseases (COPD), rheumatoid arthritis, inflammatory bowel disease, crohn's disease and multiple sclerosis. Consequently the development of PDE4 inhibitors as therapeutic agents for these diseases has been a major pharmaceutical focus. PDE4 indirectly controls the degree of bronchodilation. In the inflammatory cells cAMP is a negative regulator of the primary activating pathways such as cytokine release by T-cells. Inhibition of the PDE4 isozymes in these cells results in elevated cAMP levels and consequent inactivation of the inflammatory response. In addition to the direct role of cAMP in inflammatory cell function, elevated cAMP levels also lead to smooth muscle relaxation. Consequently, inhibition of PDE4 activity leading to higher cAMP levels causes bronchodilation thereby alleviating symptoms of respiratory diseases such as asthma or COPD.
Also, inhibition of PDE4 enzyme increases levels of cAMP and Cyclic AMP modulates the activity of most of the cells that contribute to the pathophysiology of allergic asthma. Elevation of cAMP would produce beneficial effects, some of which include apart from airway smooth muscle relaxation, inhibition of mast cell mediator release, suppression of neutrophil degranulation, inhibition of basophil degranulation and inhibition of monocyte and macrophage activation. The connection between PDE4 activity and cognition has been speculated ever since the discovery that the cAMP-regulating dunce gene of the fruit fly encodes a PDE4 homo\ogae(Nature, 1981, 289,5793, 79-1; J. mol. UoI, 1991,222, 3, 553-565).
Current drug discovery efforts involved the design of the PDE4 inhibitors with reduced side effects at the same time maintaining the anti inflammatory properties of rolipram. Compounds like Cilomilast, roflumilast, Lirimilast and AWD- 12-281 belong to the second generation PDE4 inhibitors.
1. Patent application WO93/19749 claims the compounds shown below which are useful for allergy and inflammatory states. - A -
Figure imgf000006_0001
One of the representative examples of this patent is as given below.
Figure imgf000006_0002
2. Patent US5811455 claims the compounds of formulae AA and BB
Figure imgf000006_0003
One of the representative examples of this invention is
Figure imgf000006_0004
3. WO2006011024 Patent application claims the compounds of generic formula
Figure imgf000006_0005
One of the representative compounds is as given below and the compounds of invention claims for asthma and chronic obstructive pulmonary disease apart from other disease states.
Figure imgf000007_0001
Challenges that are facing the PDE4 inhibitors are mainly nausea, vomiting, increased gastric acid secretion which may be because of selectivity towards binding sites. Based on the prior art reports, compounds with selectivity for the high-affinity rolipram binding site causes side effects where as compounds with selectivity for low-affinity rolipram binding site are expected to have better therapeutic effects compared to rolipram (J Biol. Chem. 1992,267(3): 1798-1804; J. Biol. Chem. 1999,274(17):11796-11810). Other side effects include cardiac dysarhythmias, vasculitis and osteoporosis.
As described above, as regulation of intracellular signaling is coordinated by PDE4, It has become a validated target for the development of therapeutics for inflammatory diseases such as asthma and COPD. PDE4 also has been shown to be a potential target for depression, memory enhancement, cardiovascular disease and osteogenesis.
During the course of our research aimed at the development of novel anti-asthmatic compounds having potential PDE4 inhibitory activity, we have filed a patent application in India bearing No. 1647/MUM/2006 dated September 11 , 2006 and corresponding PCT publication No 2008/032171, published on March 20, 2008, incorporated herein by reference in their entireties, for a novel series of heterocyclic compounds useful for the treatment of inflammatory and allergic disorders. Summary of the invention
According to the present invention the compounds are represented by the general formula (I)
Figure imgf000008_0001
General Formula (I) their analogues, derivatives, tautomers, stereoisomers, enantiomers, diastereomers, polymorphs, pharmaceutically acceptable salts, pharmaceutically acceptable hydrates, pharmaceutically acceptable solvates, N-oxides and bioisosteres
Wherein
Ring A is selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl Z is selected from C(O), NR1, S(O)1n, C(O)NR1, NR^CO), CR2R3,
CR2R3C(O), CR2R3O CR2R3, C(O)CR2R3, CR2R3C(O)C(O), C(O)C(O)CR2R3,
NR1C(S), C(S)NR1, CR2R3S(O)1n, S(O)1nCR2R3, S(O)1nNR1, NR1S(O)n,,
NR1S(O)01NR1;
R1 is selected from hydrogen or substituted or unsubstituted alkyl; R2 and R3 are independently selected from hydrogen, C1-C6 straight or branched alkyl, C2-C6 straight or branched alkenyl, alkylamino, alkyl halo, alkyl hydroxy, acyl, alkoxy; or
R2 and R3 together with the carbon they are attached form a C3 to C5 substituted or unsubstituted spiro ring; Ring B is selected from substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl m represents an integer ranging from O, 1 or 2; In another embodiment the present invention relates to compounds represented by general formula (II)
Figure imgf000009_0001
General formula (II) Wherein
Ring A is as defined above; Z is as defined above;
Hy represents substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl; In yet another embodiment the present invention relates to compounds represented by general formula (III)
Figure imgf000009_0002
General formula (III) their analogues, derivatives, tautomers, stereoisomers, enantiomers, diastereomers, polymorphs, pharmaceutically acceptable salts, pharmaceutically acceptable hydrates, pharmaceutically acceptable solvates, N-oxides and bioisosteres Wherein
Z is as defined above;
Hy represents substituted or unsubstituted heterocyclyl or substituted or unsubstituted heteroaryl;
In yet another embodiment, the present invention relates to compounds represented by general formula (III) wherein Z is C(O) and Hy is as defined above.
In yet another embodiment, the present invention relates to compounds represented by general formula (III) wherein Z is NR1 and Hy is as defined above. In yet another embodiment, the present invention relates to compounds represented by general formula (III) wherein Z is S(O)n,, Hy and m are as defined above. In yet another embodiment, the present invention relates to compounds represented by general formula (III) wherein Z is CR R , Hy and m are as defined above
In yet another embodiment, the present invention relates to compounds represented by general formula (I) wherein ring A represents but is not limited to substituted or unsubstituted moieties selected from
Figure imgf000010_0001
Figure imgf000011_0001
Wherein
X is selected from hydrogen, hydroxyl, halo, substituted or unsubstituted amino, nitro, cyano, substituted or unsubstituted alkyl, haloalkyl, haloalkyloxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkoxy, amido, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heteroaryl, NR1S(O)n)R1, R1C(O)R1, R1OC(O)R1, -SR1, - SOR1, COOR1, -NR2R3, -NR1C(O)R1;
R1, R2 and R3 are as defined above; n represents an integer ranging from O, 1, 2 or 3;
In yet another embodiment the present invention relates to compounds represented by general formula (I) wherein ring B represents but is not limited to substituted or unsubstituted moieties selected from
Figure imgf000012_0001
Wherein X is as defined above;
In yet another embodiment, the representative compounds of the present invention are listed below without limiting the scope the invention
(4-Difluoromethoxy-8-nitro-dibenzofuran-l-yl)-(2, 3-dihydro-pyrrolo [3, 2- cjpyridin-l -yl)-methanone
N-[6-Difluoromethoxy-9-(2, 3-dihydro-pyrrolo [3, 2-c] pyridine- 1-carbonyl) dibenzofuran-2-yl]-methanesulfonamide
N-[9-(2, 3-Dihydro-pyrrolo [3, 2-c] pyridine- 1 -carbonyl)-6-methoxy- dibenzofuran-2-yl]-methanesulfonamide N-[5-(2, 3-Dihydro-pyrrolo[3,2-c]pyridine-l-carbonyl)-8-methoxy-9-methyl- 9H-carbazol-3-yl]- methanesulfonamide
(7-Bromo-2, 3-dihydro-pyrrolo [3, 2-c]pyridin-l-yl)-(4-difluoromethoxy-8~ nitro-dibenzofuran -1 -yl)-methanone Present invention also relates to a process for the preparation of the novel heterocyclic compounds of general formula (I).
The compounds of the present invention may inhibit or regulate the TNF alpha production and are useful in the treatment of allergic and inflammatory diseases including asthma, allergic conditions, allergic conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, diabetes, Crohn's disease, allergic rhinitis, endotoxic shock and adult respiratory distress syndrome. The compounds of present invention are particularly useful for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Detailed description of the invention:
Definitions:
The term "alkyl" refers to a straight or branched chain saturated aliphatic hydrocarbon that may be substituted or unsubstituted. Examples of "alkyl" include but are not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, n-pentyl, isobutyl and the like.
The term "alkenyl" used herein, either alone or in combination with other radicals, denotes a straight or branched C2-C6 aliphatic hydrocarbon chain containing one or more carbon to carbon double bonds that may be optionally substituted with multiple degrees of substitution being allowed. The term "alkenyl" includes dienes and trienes of straight and branched chains and are selected form Vinyl allyl, 2- butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3hexenyl, 4- hexenyl, 5-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6- heptenyl. The term "alkynyl" used herein, either alone or in combination with other radicals, denotes a straight or branched chain aliphatic hydrocarbon containing two to eight carbons with one or more triple bonds which may be substituted or unsubstituted. The term "alkynyl" includes di-and tri-ynes, such as ethynyl, 1- propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl,l-pentynyl, 2-pentynyl, 3- pentynyl, 4-pentynyl, 1-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, and the like.
The term "acyl" refers to the group-C(O)Rd where Rd is Alkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl each as herein defined and examples of which include acetoyl, propanoyl, butanoyl, iso-butanoyl, pentanoyl, benzoyl and the like, which may be substituted or unsubstituted.
"Alkoxy" refers to a group -ORC where Rc is alkyl as herein defined. Representative examples include but are not limited to methoxy, ethoxy and like. "Alkylamino" refers to the group — N(RC)2 where one Rc is alkyl and the other Rc independently is H or alkyl as herein defined. "Alkylhalo" refers to the group 'Rc-halogen' where R0 is alkyl defined as above and halogen is selected from Fluorine, Chlorine, Bromine and Iodine and it can be haloalkyl, dihaloalkyl or trihaloalkyl or polyhaloalkyl like methylene chloride,CF3,CHF2,CF2-CF3 etc.
"Halogen" refers to Fluorine, Chlorine, Bromine or Iodine. "Alkylhydroxy or hydroxyalkyl" refer to the group R0OH where Rc is alkyl as herein defined and the representative examples include but are not limited to hydroxy methyl, hydroxy ethyl, hydroxy propyl and like.
"Aryl" refers to optionally substituted aromatic ring system having the carbon atoms in the range of five to ten carbon atoms and they may be monocyclic, bicyclic or polycyclic and unsaturated or partially saturated and one or more carbons may optionally be replaced by one or more heteroatoms selected from N, O and S. Exemplary aryl groups include phenyl, naphthyl, indanyl, biphenyl and like. "Aminosulfonyl" refers to -NH-SO2-; "Carboxy" refers to -COO-; "Carbamoyl" refers to the group -C(O)NH2; "Sulfonyl" Refer to the group -S(O)2-; "Sulfinyl" Refer to the group -S(O)-
"Thio" refers to "-S-"; "Sulfamido" refers to a group -S(O)2NH2; "Carboxamido " refers to group -CO-NH2; "Guanidyl" refers to a group -NH-C (=NH)-NH2; "Ureido or uredyl" group refers to -NH-C(O)-NH2;
The term "cycloalkyl" used herein, either alone or in combination with other radicals, denotes mono, bicyclic or polycyclic saturated, partially saturated hydrocarbon ring system of about 3 to 12 carbon atoms which may be substituted or unsubstituted. Exemplary "cycloalkyl" groups include but are not limited to cyclopopyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, perhydronapthyl, adamantyl, noradamantyl or spirobicyclic groups such as spiro (4,4)non-2-yl.
The term "cycloalkylalkyl" refers to a cycloalkyl ring containing 3 to 12 carbon atoms directly attached to an alkyl group which is then attached to the main structure at any carbon atom in the alkyl group that results in a stable structure such as cyclopropylmethyl, cyclobutylmethyl and the like.
"Heteroaryl "refers to monocyclic aromatic ring systems or fused bicyclic aromatic ring systems comprising two or more aromatic rings preferably two to three ring systems. These heteroaryl rings contain one or more nitrogen, sulfur and or oxygen atoms where N-oxides sulfur oxides and dioxides are permissible heteroatom substitutions. The term includes ring(s) optionally substituted with halogens, nitro, amino, alkoxy, alkyl sulfonyl amino, alkylcarbonylamino, carboxy, alkyl carbonoyl, hydroxy, and alkyl. Examples of heteroaryl groups include furan, thiophene, pyrrole, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, isoxazole, oxadiazole, thiadiazole, isothiazole, pyridine, pyridazine, pyrazine, pyrimidine, quinoline, isoquinoline, benzofuran, benzothiophene, indole, indazole, chromanyl, iso chromanyl and the like.
"Heterocyclyl" refers to a stable 3 to 15 membered ring that is either saturated or has one or more degrees of unsaturation or unsaturated. These heterocyclic rings contain one or more heteroatoms selected from the group consisting of nitrogen sulfur and/or oxygen atoms where N-oxides, sulfur oxides and dioxides are permissible heteroatom substitutions. Such a ring may be optionally fused to one or more of another heterocyclic ring(s), aryl ring(s) or cycloalkyl ring(s). Examples of such groups may be selected from the group comprising azetidinyl, acridinyl, pyrazolyl, imidazolyl, triazolyl, pyrrolyl, thiophenyl, thiazolyl, oxazolyl, isoxazolyl, furanyl, pyrazinyl, tetrahydroisoquinolinyl, piperidinyl, piperazinyl, morpholinyl, thiomorphonilyl, pyridazinyl, indolyl, isoindolyl, quinolinyl, chromanyl and the like. "Heterocyclylalkyl" refers to a heterocyclic ring radical defined above directly bonded to an alkyl group. The heterocyclylalkyl radical may be attached to the main structure at carbon atom in the alkyl group that results in the creation of a stable structure.
Unless otherwise specified, the term "substituted" as used herein refers to substitution with any one or any combination of the following substituents: hydroxy, halogen, carboxyl, cyano, nitro, oxo (=0), thio (=S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclylalkyl ring, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring, substituted or unsubstiuted guanidine, - COOR5, -C(O)R5, -C(S)R5, -C(O)NR5R6, - C(O)ONR6R7, -NR5CONR6R7, - N(R5)SOR6, -N(R5)SO2R6, -(=N-N(R5)R6), - NR5C(O)OR6, -NR5R6, -NR5C(O)R6, - NR5C(S)R6, -NR5C(S)NR6R7, -SONR5R6, - SO2NR5R6, -OR5, -OR5C(O)NR6R7, - OR5C(O)OR6, -OC(O)R5, -OC(O)NR5R6, - R5NR6C(O)R7, -R5OR6, -R5C(O)OR6, - R5C(O)NR6R7, -R5C(O)R6, -R5OC(O)R5, -SR5, - SOR5, -SO2R5, and -ONO2, wherein R5, R6 and R7 are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted heterocyclylalkyl ring, substituted or unsubstituted heteroarylalkyl, or substituted or unsubstituted heterocyclic ring. Alternately R6 and R7 together along with the nitrogen they are attached with, form a 4 to 8 membered ring which can be substituted or unsubstituted. According to one embodiment, the substituents in the aforementioned "substituted" groups cannot be further substituted. For example, when the substituent on "substituted alkyl" is "substituted aryl" the substituent on "substituted aryl" cannot be "substituted alkenyl"
"Stereoisomers" refer to certain compounds described herein containing one or more chiral centres or may otherwise be capable of existing as multiple stereoisomers. Scope of the present invention includes pure stereoisomers as well as mixtures of stereoisomers such as purified enantiomers/diastereomers or enantiomerically/diastereomerically enriched mixtures.
"Bioisosteres" refers to compounds or groups that possess near molecular shapes and volumes, approximately the same distribution of electrons and which exhibit similar physical properties such as hydrophobicity. Bioisostereic compounds affect the same biochemically associated systems as agonist or antagonists and thereby produce biological properties that are related to each other.
"Pharmaceutically acceptable salts" forming part of this invention include salts derived from inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, Al, Mn; salts of organic bases such as N,N'-diacetylethylenediamine, 2- dimethylaminoethanol, isopropylamine, morpholine, piperazine, piperidine, procaine, diethylamine, triethylamine, trimethylamine, tripropylamine, tromethamine, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, dialkylamine, trialkylamine, thiamine, aminopyrimidine, aminopyridine, purine, pyrimidine, spermidine, and the like; chiral bases like alkylphenylamine, glycinol, phenyl glycinol and the like, salts of natural amino acids such as glycine, alanine, valine, leucine, isoleucine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids such as D-isomers or substituted amino acids; salts of acidic amino acids such as aspartic acid, glutamic acid; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl, ammonium or substituted ammonium salts. Salts may include acid addition salts where appropriate which are sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, methanesulfonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates and the like.
"Pharmaceutically acceptable solvates" may be hydrates or comprising other solvents of crystallization such as alcohols.
"Compounds of the invention" or "present invention" refers to the compounds of the present invention represented by general formula (I) as here in defined, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their bioisosters, their diastereomers, their polymorphs, their enantiomers, their appropriate N-oxides, their pharmaceutically acceptable salts, their pharmaceutically acceptable hydrates, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. The compounds of the present invention may inhibit or regulate the TNF alpha production and are useful in the treatment of allergic and inflammatory diseases including asthma, inflammatory diseases, allergic conditions, allergic conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, diabetes, Crohn's disease, allergic rhinitis, endotoxic shock and adult respiratory distress syndrome. The compounds of present invention are particularly useful for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Another embodiment of the present invention is a method of treating an inflammatory disease, disorder or condition associated with undesirable inflammatory immune response or a disease or condition induced by or associated with an excessive secretion of TNF-α and PDE-4 in humans. The method includes administering to the human a therapeutically effective amount of a compound according to the general formula (I). "Method of treating" includes preventing or delaying the appearance of clinical symptoms, inhibiting the state disorder or condition, relieving the disease causing regression of the disease.
General method of preparation
The compounds of general formula (I) can be synthesized by the scheme illustrated below:
Figure imgf000019_0001
Figure imgf000019_0002
General Formula 1
The compound of general formula aa (wherein ring A and X are as defined in the specification) is oxidized using suitable oxidizing agents such as potassium permanganate, sodium chlorite, potassium dichromate, potassium chromate, pyridinium dichlorochromate, pyridinium chlorochromate, Jone's reagent (solution of chromium trioxide in concentrated sulfuric acid) and the like in the presence of suitable solvents such as acetone, acetone-water, sulfamic acid, glacial acetic acid, water, DCM, chloroform, EDC and the like to form the compound of general formula ab. The compound of general formula ab is then converted to either acid chloride or ester using suitable chlorinating agents such as thionyl chloride, phosphorus oxychloride, phosphorus trichloride or suitable reagents such as DCC/p- Nitrophenol in the presence of suitable solvents such as benzene, dimethylformide (DMF), tetrahydrofuran (THF), ethyl acetate, dichloromethane, chloroform and the like. The acid chloride or ester thus formed is then reacted with suitable substituted or unsubstituted group represented by ring B in presence of suitable bases such as N,N-diisopropylethylamine (DIPEA), triethylamine (TEA), sodium methoxide, sodium hydride, potassium tertiary.butoxide, sodium hydroxide and the like in the presence of suitable solvents such as tetrahydrofuran, dimethylformamide (DMF), acetonitrile, water and the like to obtain the compound of general formula 1. Alternately compound of general formula ab can be converted to compound of general formula 1 via mixed anhydride method using suitable reagent such as alkyl chloroformate or aryl chloroformate in the presence of suitable solvents such as tetrahydrofuran (THF), dioxane, chloroform, ethylene dichloride (EDC), ethyl acetate and the like. Also the compound of general formula ab is converted to compound of general formula ac using coupling reagent such as l-ethyl-(3,3'- dimethylaminopropyl)-carbodiimide (EDCI), l,l'-carbonyldiimidazole (CDI), N,N'- dicylohexylcarbodiimide (DCC), 1- hydroxyl-benzotriazole (HOBt) and the like tetrahydrofuran, dichloromethane, chloroform, ethyl acetate and the like.
The stereoisomers of the compounds forming part of this invention may be prepared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomer form or by resolving the mixture of stereoisomers by conventional methods. Some of the preferred methods include use of microbial resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartaric acid, lactic acid, and the like wherever applicable or chiral bases such as brucine, cinchona alkaloids and their derivatives and the like. Different polymorphs of a compound of general formula (I) of present invention may be prepared by crystallization of the compound of formula (I) under different conditions .For example making use of commonly used solvents or their mixtures for recrystallization, crystallization at different temperature ranges, different cooling techniques like very fast to very slow cooling during crystallization procedure, by exposing to room temp, by heating or melting the compound followed by gradual cooling and the like. The presence of polymorphs may be determined by one or more methods like solid probe NMR spectroscopy, DSC, TGA, Powder X- Ray diffraction and IR. The present invention also provides pharmaceutical compositions containing the compounds of invention as defined above, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their bioisosters, their polymorphs ,their enantiomers, their diastereomers, their pharmaceutically acceptable salts or their pharmaceutically acceptable solvates in combination with the suitable pharmaceutically acceptable carriers, diluents. The pharmaceutical compositions according to the present invention are useful for the treatment of allergic and inflammatory diseases including asthma, inflammatory diseases, allergic conditions, allergic conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, diabetes, Crohn's disease, allergic rhinitis, endotoxic shock and adult respiratory distress syndrome and related diseases. The pharmaceutical composition may be tablets, capsules, powders, syrups, solutions, suspensions, sprays and like and may contain flavorants, sweeteners etc., in a suitable solid or liquid carriers or diluents or in a suitable sterile media to form injectable solutions or suspensions. It is understood that in any of the above schemes any reactive group in the substrate molecule may be protected according to any conventional procedure known in the prior art. Suitable protecting groups comprise N-Boc, N-Cbz, N-Fmoc, alkyl, benzophenoneimine for protection of amino group, acetal protection for aldehyde, ketal protection for ketone. The invention also encompasses prodrugs of compounds of the invention, which on administration undergo chemical conversion by metabolic processes before becoming active pharmacological substances, In general, such prodrugs will be functional derivatives of compounds of invention, which are readily convertible in vivo into compounds of the invention. The invention also encompasses the active metabolites of the compounds of the present invention of general formula (I). Experimental data
Preparation of Intermediate:
Figure imgf000022_0001
Procedure: Prepared according to the procedure reported in US 2007/0105855.
Figure imgf000022_0002
Procedure: Prepared according to the procedure reported in WO 2008/005955.
Figure imgf000022_0003
Procedure: Prepared according to the procedure reported in US 2007/0105855.
Figure imgf000022_0004
Procedure: Prepared according to the procedure reported in WO 2008/005955. Example 1
Figure imgf000023_0001
Preparation of (4-Difluoromethoxy-8-nitro-dibenzofuran-l-yl)-(2, 3-dihydro- pyrrolo [3, 2-c]pyridin-l-yl)-methanone
To a solution of 4-difluoromethoxy-8-nitro-dibenzofuran-l-carboxylic acid (200 mg, 0.6173 mmol) in toluene(3ml) was added thionyl chloride (0.460ml, 6.191mmol) and mixture was stirred at reflux temperature for about 3 hours, cooled the reaction mixture to room temperature and toluene was evaporated under vacuum. Repeated 4 to 5 times to remove excess thionyl chloride. The above acid chloride was dissolved in tetrahydrofuran and added N, N-diisopropyl-N-ethyl amine (ImI) followed by 2, 3-dihydro-lH-pyrrolo [3, 2-c]-pyridine (80 mg, 0.6167 mmol) at room temperature. The reaction mass was stirred at room temperature for 4 hours. Added water and the product was extracted with 10% MeOH/CHCl3 which was concentrated under vacuum and purified with column chromatography to afford the titled compound (160 mg, 61% yield).
1H NMR (300 MHz, CDCl3) δ 3.25-3.31 (t, 2H), 4.25 (br s, 2H), 6.66-7.14 (t, 1 H, J = 72.3 Hz), 7.47-7.56 (m, 2 H), 7.54-7.78 (d, IH5 J = 9.09 Hz), 8.34-8.48 (m, 3H), 8.83 (d, IH, J = 1.9 Hz). MS m/z [M+l] 426.1.
Example 2
Figure imgf000023_0002
Preparation of N-[6-Difluoromethoxy-9-(2, 3-dihydro-pyrrolo [3, 2-c]pyridine-l- carbonyl) -dibenzofuran-2-yl]-methanesulfonamide
To the clear solution of example 1 (160 mg, 0.388 mmol) in a mixture of solvent (EtOH: THF: H2O : : 2: 1 :0.5, 15 ml) at 85 0C was added ammonium chloride (75 mg) and iron powder (75 mg). The reaction mixture was stirred at the same temperature for 1 hour. The reaction mass was cooled to room temperature and filtered through celite bed. To the filtrate was added 20 ml saturated brine and then extracted with 10% MeOH/CHCl3 which was dried with anhydrous sodium sulphate and concentrated under vacuum to afford crude amine (150 mg). The crude amine was dissolved in a mixture of dichloromethane (3.5 ml) and THF (3.5 ml) and cooled to 0 to 5 0C. To this mixture was added a mixture of methanesulphonyl chloride, pyridine and the above solvent at the same temperature and stirred for 45 min. The reaction mass was quenched with water and extracted with 20% MeOH/CHCl3 which was dried with anhydrous sodium sulphate and concentrated under vacuum and purified by column chromatography to afford the titled compound (46 mg, 20 % yield) as an off-white solid. HPLC Purity: 93.09 %. IR (KBr) cm'l 3413, 3068, 2853, 1659, 1595, 1484, 1464, 1439, 1391, 1377, 1317, 1290, 1153, 1111.
1H NMR (300 MHz, DMSO-cfc) δ 2.82 (s, 3 H), 3.16 (s, 2H), 4.03 (br s, 2H), 7.31 (s, 0.3 H), 7.43-7.45 (m, 1.3 H), 7.56 -7.65 (m, 4.4 H), 7.81-7.84 (m, 2 H), 8.43 (s, IH), 9.89 (br s, 1 H). MS m/z [M+l] 474.1.
Example 3
Figure imgf000024_0001
Step 1: Preparation of (2,3-Dihydro-pyrrolo[3, 2-c]pyridin-l-yI)-(4-methoxy-8- nitro-dibenzofuran-l-yl)-methanone
To a solution of 4-methoxy-8-nitro-dibenzofuran-l-carboxylic acid (500 mg, 1.639 mmol), prepared according to the procedure described in US 2007/0105855, in benzene (10 ml) was added thionyl chloride (5 ml) and cat. amount of dimethylformamide. The mixture was stirred at reflux temperature for about two and half hours. Cooled the reaction mixture to room temperature and benzene was evaporated under vacuum, repeating 4 to 5 times to remove excess thionyl chloride. The above acid chloride was dissolved in tetrahydrofuran (15 ml) and to this was added N, N-diisopropyl-N-ethyl amine (ImI) at room temperature followed by 2, 3- dihydro-lH-pyrrolo[3,2-c]pyridine (238 mg, 1.967 mmol). The reaction mass was stirred at room temperature for 16 hours. Added water and the tetrahydrofuran was removed under vacuum and the precipitated solid was filtered and dried to afford the titled compound (480 mg, 76% yield) as an off-white solid.
1H NMR (300 MHz, CDCl3) δ 3.36 (br s, 2H), 4.15 (s, 3H), 4.37 (br s, 2H), 7.14- 7.16 (m, IH), 7.38 (m, IH), 7.56-7.59 (m, IH), 7.73-7.76 (d, IH5 J = 9.3 Hz), 8.31 (m, IH), 8.41-8.49 (m, 2H)5 8.88 (d, IH, J = 1.9 Hz). MS m/z [M+l] 390.2!
Step2: Preparation of N-[9-(2, 3-Dihydro-pyrroIo [3, 2-c]pyridine-l-carbonyI)-6- methoxy-dibenzofuran-2-yl]-methanesulfonamide
To the clear solution of (2, 3-dihydro-pyrrolo[3,2-c]pyridin-l-yl)-(4-methoxy-8- nitro-dibenzofuran-l-yl)-methanone (300 mg ) in a mixture of solvent (EtOH: THF: H2O:: 2:1:0.5) at 85 0C was added ammonium chloride (150 mg) and iron powder (150 mg). The reaction mixture was stirred at the same temperature for lhour. The reaction mass was cooled to room temperature and filtered through celite bed. To the filtrate was added 20 ml saturated brine and then extracted with 10% MeOH/CHCl3 which was dried with anhydrous sodium sulphate and concentrated under vacuum to afford crude amine (160 mg). The crude amine was dissolved in tetrahydrofuran (5 ml) and cooled to 0-5 C. To this mixture was added a mixture of methanesulphonyl chloride (0.091ml, 1.114 mmol), pyridine (0.212ml, 2.674 mmol) and the above solvent at the same temperature and stirred for 45 min. The reaction mass was quenched with water and extracted with 20% MeOH/CHCl3 which was dried with anhydrous sodium sulphate and concentrated under vacuum and purified by column chromatography to afford the titled compound (70 mg, 36 % yield) as an off-white solid. mp: 258.6-259.6 0C. HPLC Purity: 95.81 %.
IR (KBr) cm'l 3431, 3025, 2926, 2851, 1674, 1636, 1607, 1482, 1410, 1325, 1289, 1152, 1104, 822. 1H NMR (300 MHz, DMSO-^) δ 2.88 (s, 3H), 3.25-3.41 (t, 2H), 4.08 (s, 3H), 4.18- 4.24 (t, 2H), 7.33 (d, 1 H, J = 8.1 Hz), 7.42 (d, 1 H, J = 8.4 Hz), 7.64 (d, 1 H, J = 8.4 Hz), 7.73-7.86 (m, 3 H, ), 8.59 (d, 1 H, J = 6.6 Hz), 8.68 (s, 1 H), 9.81 (s, 1 H). MS m/z [M+l] 438.2.
Example 4
Figure imgf000026_0001
Step 1: Preparation of (2, 3-Dihydro-pyrrolo [3, 2-c]pyridin-l-yl)-(l-methoxy-9- methyl-6-nitro-9H-carbazol-4-yl)-methanone
reflux
18 h
Figure imgf000026_0002
Figure imgf000026_0003
To the suspension of l-methoxy-9-methyl-6-nitro-9H-carbazole-4-carboxylic acid (prepared as per the procedure mentioned in US20070105855), (400 mg, 1.33 mmol) in benzene (15 ml) was added thionyl chloride (5 ml) and refluxed for 4 hours. The reaction mixture was concentrated under vacuum completely. Benzene (10 ml) was added and removed under vacuum. This process was repeated again three times. The crude acid chloride was suspended in tetrahydrofuran (15 ml) and cooled to 0 0C and added N, N-diisopropyl-N-ethyl amine (0.35 ml) followed by 2, 3-Dihydro-lH- pyrrolo[3,2-c]pyridine (192 mg, 1.59 mmol). The reaction mass was stirred overnight at room temperature. The reaction mass was concentrated under vacuum completely and then water was added, stirred for about one hour. The precipitated solid was filtered, washed with water and dried under vacuum to afford the titled compound (350 mg, 65% yield) as an off-white solid.
1H NMR (300 MHz, CDCl3) δ 3.26-3.32 (t, 2H), 4.09 (s, 3H), 4.27 (s, 3H), 4.29-4.35 (m, 2H), 6.91-6.94 (m, IH), 7.04-7.07 (d, IH, J = 8.1 Hz), 7.33-7.35 (d, I H1 J = 8.1 Hz), 7.41-7.44 (d, 1 H, J = 9.0 Hz)5 8.33-8.40 (m, 3H), 8.83 (d, 1 H, J = 1.8 Hz). MS m/z [M+l] 403.3.
Step 2: N-[5-(2, 3-Dihydro-pyrrolo[3,2-c]pyridine-l-carbonyl)-8-methoxy-9- methy l-9H-carbazol-3-yl] -methanesulf onamide
To the suspension of (2,3-dihydro-pyrrolo[3,2-c]pyridin-l-yl)-(l-methoxy-9-methyl- 6-nitro-9H-carbazol-4-yl)-methanone (390 mg, 0.969 mmol) in EtOH:THF:H2O (2:1 :0.5, 11 ml) was added ammonium chloride (390 mg) and iron powder (390 mg)and refluxed for about two and half hours. The reaction mass was cooled to room temperature, filtered through celite bed and washed with chloroform. The filtrate was concentrated under vacuum and the resulted mass was dissolved in ethyl acetate which was washed with brine, dried with anhydrous sodium sulphate and concentrated under vacuum to afford crude amine (295 mg). The crude amine was dissolved in mixture of dichloromethane and tetrahydrofuran (1 :1, 15 ml). To this a mixture of pyridine (0.34 ml) and methanesulphonyl chloride (0.131 ml) in tetrahydrofuran (2 ml) was added at 0 0C and stirred at the same temperature for 1 hour. The reaction mass was diluted with water and extracted with ethyl acetate which was washed with brine, dried with anhydrous sodium sulphate and concentrated under vacuum and purified by column chromatography eluted with 3 % MeOH/CHCl3 to afford the titled compound (130 mg, 30 % yield) as off-white solid, mp (DSC): 270.75 0C. HPLC Purity: 99.05 %. IR (KBr) cm"l 3431, 2936, 2835, 2695, 1664, 1597, 1575, 1497, 1454, 1435, 1380, 1329, 1304, 1276, 1258, 1151.
1H NMR (300 MHz, OMSO-dβ) δ 2.69 (s, 3H), 3.12 (m, 2H), 3.92- 4.04 (br s, 5H), 4.16 (s, 3H), 7.13-7.22 (m, 2H), 7.32-7.35 (dd, IH, J = 1.8, 8.8 Hz), 7.58-7.63 (m, 2H), 8.14-8.35 (m, 2H), 9.48 (s, IH). MS m/z [M+l] 451.3, [M+Nal] 473.3.
Example 5
Figure imgf000028_0001
Step 1: 2, 3-Dihydro-pyrroIo [3, 2-c]pyridine-l-carboxyIic acid tert-butyl ester
Figure imgf000028_0002
Procedure: Prepared according to the procedure reported in J. Org. Chem. 64, 9430- 9443 (1999).
Step 2: 2, 3-Dihydro-lH-pyrrolo [3, 2-c]pyridine
Figure imgf000029_0001
The mixture of 2, 3-Dihydro-pyrrolo[3,2-c]pyridine-l-carboxylic acid tert-butyl ester
(2.2 g, 0.01 mol) in 1, 2-dimethoxyethane (10 ml) and cone. HCl (5 ml) was stirred at
50-55 0C for 30 min. The reaction mixture was cooled to room temperature, basified with saturated sodium bicarbonate and extracted with chloroform which was dried with anhydrous sidium sulphate and concentrated under vacuum to afford the titled compound (670 mg, 60% yield).
1H NMR (300 MHz, OMSO-d6) δ 2.94 (t, 2H), 3.51 (t, 2H)5 6.40 (d, IH, J = 5.4 Hz),
6.51 (s, IH), 7.89-7.95 (m, 2H). MS m/z [M+l] 121.3.
Step 3: 2, 3-Dihydro-lH-pyrrolo [3, 2-c]pyridine hydrochloride
Figure imgf000029_0002
To the solution of 2, 3-dihydro-pyrrolo [3, 2-c]pyridine-l-carboxylic acid tert-butyl ester 5.2 g, 0.0236 mol) in dichloromethane (30 ml) and ethyl acetate (60 ml) was added dry HCl in ethyl acetate (20 ml) at room temperature and stirred for 2 hours.
The precipitated solid was filtered, washed with ethyl acetate and dried under vacuum to afford titled compound (2.2 g, 55.5 % yield) as an off-white solid which is hygroscopic. 1H NMR (300 MHz, DMSO-^) δ 3.11 (t, 2H)5 3.80 (t, 2H), 6.62 (d, IH, J = 6.7 Hz),
7.95-8.00 (m, 2H)5 8.78 (s, IH, D2O exchangeable), 13.29 (br s, IH, D2O exchangeable).
MS m/z [M+l] 121.1. Step 4: 7-Bromo-2, 3-dihydro-lH-pyrrolo [3, 2-c]pyridine
Figure imgf000030_0001
To the solution of 2, 3-dihydro-lH-pyrrolo[3,2-c]pyridine hydrochloride (500 mg, 3.205 mmol) in dry dimethylformamide (10 ml) was added N-bromosuccinimide (599 mg) and stirred overnight at room temperature. The reaction mixture was diluted with water and basified with sodium bicarbonate and extracted with ethyl acetate which was dried with anhydrous sodium sulphate, concentrated under vacuum and purified by column chromatography eluted with 50 % ethyl acetate in hexane to afford the titled compound (200 mg, 31 % yield).
IR (KBr) Cm 4 3202, 3167, 2908, 1705, 1609, 1503, 1476, 1438, 1311, 1257, 1152,
1103, 1031, 883.
1H NMR (300 MHz, DMSO-J15) δ 3.07 (t, 2H), 3.57 (t, 2H), 6.65 (s, IH, D2O exchangeable), 7.91 (s, IH), 8.03 (s, IH). MS m/z [M+] 198.9, [M+2] 200.9.
Step 5: (7-Bromo-2, 3-dihydro-pyrrolo [3, 2-c]pyridin-l-yl)-(4-difluoromethoxy- 8-nitro-dibenzofuran-l-yl)-methanone
To a solution of 4-difluoromethoxy-8-nitro-dibenzofuran-l-carboxylic acid (200mg, 0.6191 mmol) in toluene (3ml) was added thionyl chloride (0.460ml, 6.191mmol) and catalytic amount of DMF. The mixture was stirred at 90 0C for about two and half hours, cooled to room temperature and toluene was evaporated under vacuum, repeating 4 to 5 times to remove excess thionyl chloride. The above acid chloride was dissolved in tetrahydrofuran and to this was added N, N-diisopropyl-N-ethyl amine (0.128 ml) at room temperature followed by 7-bromo-2, 3-dihydro-lH- pyrrolo[3,2-c]pyridine (123 mg, 0.6191 mmol). The reaction mass was stirred at room temperature for 48 hours. Added water and the product was extracted with CHCl3 which was concentrated under vacuum and purified with column chromatography to afford the titled compound (40 mg, 30% yield).
HPLC Purity: 95.65 %.
1H NMR (300 MHz, DMSO-J6) δ 3.06-3.17 (m, 2H), 3.56-3.62 (t, 2H), 7.36-7.85 (t,
IH, J = 72.6 Hz), 7.61-7.63 (m, 1 H), 7.92 (s, IH), 8.07-8.15 (m, 3 H), 8.51-8.54 (m,
IH), 9.82 (s, IH).

Claims

1. The compound of formula
Figure imgf000032_0001
their analogues, derivatives, tautomers, stereoisomers, enantiomers, diastereomers, polymorphs, pharmaceutically acceptable salts, pharmaceutically acceptable hydrates, pharmaceutically acceptable solvates, N-oxides and bioisosteres wherein
Z is selected from C(O), NR1, S(O)1n, C(O)NR1, NR^CO), CR2R3,
CR2R3C(O), CR2R3O CR2R3, C(O)CR2R3, CR2R3C(O)C(O),
C(O)C(O)CR2R3, NR1C(S)5 C(S)NR1, CR2R3S(O)111, S(O)01CR2R3, S(O)1nNR1, NR1S(OU NR1S(O)111NR1;
R1 is selected from hydrogen or substituted or unsubstituted alkyl;
R2 and R3 are independently selected from hydrogen, C1-C6 straight or branched alkyl, dialkyl, C2-C6 straight or branched alkenyl, alkylamino, alkyl halo, alkyl hydroxy, acyl, alkoxy; or R2 and R3 together with the carbon they are attached form a C3 to C5 substituted or unsubstituted spiro ring; m represents an integer ranging from O, 1 or 2;
Hy represents substituted or unsubstituted heterocyclyl or substituted or nsubstituted heteroaryl.
2. A compound according to claim 1, wherein Z is -C(O)-.
3. A compound according to claim 1, wherein Z is -NH-.
4. A compound according to claim 1, wherein Z is -CH2NH-.
5. A compound according to claim 1, wherein Z is S(0)m wherein m represents an integer ranging from 0, 1 , or 2.
6. A compound according to claim 1, wherein Hy is substituted carbazole.
7. A compound according to claim 1, wherein Hy is substituted dibenzofuran.
8. A compound according to claim I5 wherein Hy is substituted dihydro pyrrolo pyridine.
9. A compound according to claim 1, wherein the compound is selected from (4-Difluoromethoxy-8-nitro-dibenzofuran-l-yl)-(2, 3-dihydro-pyrrolo [3, 2- c]pyridin- 1 -yl)-methanone
N-[6-Difluoromethoxy-9-(2, 3-dihydro-pyrrolo [3, 2-c]pyridine-l-carbonyl) - dibenzofuran-2-yl]-methanesulfonamide
N-[9-(2, 3-Dihydro-pyrrolo [3, 2-c]pyridine-l-carbonyl)-6-methoxy- dibenzofuran-2-yl]-methanesulfonamide
N-[5-(2, 3-Dihydro-pyrrolo[3,2-c]pyridine-l-carbonyl)-8-methoxy-9-methyl- 9H-carbazol-3 -yl] - methanesulfonamide
(7-Bromo-2, 3-dihydro-pyrrolo [3, 2-c]pyridin-l-yl)-(4-difluoromethoxy-8- nitro-dibenzofuran -l-yl)-methanone
10. A process for preparing a compound according to claim 1, or a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, enaontiomer, diastereiomer or N-oxide thereof, comprising at least one of the steps of a) oxidising the compound of formula ac
Figure imgf000034_0001
ac using suitable oxidizing agents such as potassium permanganate, sodium chlorite, potassium chromate and the like to obtain the compound of formula ab
Figure imgf000034_0002
ab b) chlorinating the compound of formula ab using conventional chlorinating agents such as thionyl chloride, phosphorous trichloride, phosphorous oxychloride and the like to obtain the corresponding acid chloride
c) alternately, reacting the compound of formula ab with para nitro phenol in the presence of DCC to obtain the corresponding ester
d) reacting the acid chloride or the ester formed above with ring B in the presence of a suitable base such as sodium hydride, and the like to obtain the compound of formula 1
Figure imgf000034_0003
General Formula 1
11. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition according to claim 11, or a pharmaceutically acceptable salt thereof for use as a Phosphodiesterase 4 (PDE IV) inhibitor.
13. A method for treating an inflammatory disease, disorder or condition characterized by or associated with an excessive secretion of TNF-α and Phosphodiesterase 4 (PDE IV), which comprises administering to a subject in need thereof a therapeutically effective amount of a compound according to claim 1.
14. The method according to claim 13, wherein said inflammatory conditions and disorders are chosen from the group comprising asthma, COPD, allergic rhinitis, allergic conjunctivitis, respiratory distress syndrome, chronic bronchitis, nephritis, rheumatoid spondylitis, osteoarthritis, atopic dermatitis, eosinophilic granuloma, psoriasis, rheumatoid septic shock, ulcerative colitis, multiple sclerosis, chronic inflammation, Crohn's syndrome and central nervous system(CNS) disorders.
15. The use of the compound according to claims 1 to 9, in a medicament for the treatment of inflammatory conditions and disorders chosen from the group comprising asthma, COPD, allergic rhinitis, allergic conjunctivitis, respiratory distress syndrome, chronic bronchitis, nephritis, rheumatoid spondylitis, osteoarthritis, atopic dermatitis, eosinophilic granuloma, psoriasis, rheumatoid septic shock, ulcerative colitis, multiple sclerosis, chronic inflammation, Crohn's syndrome and, and central nervous system(CNS) disorders.
PCT/IB2009/000186 2008-06-02 2009-01-29 Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation WO2009147476A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1324/CHE/2008 2008-06-02
IN1324CH2008 2008-06-02

Publications (1)

Publication Number Publication Date
WO2009147476A1 true WO2009147476A1 (en) 2009-12-10

Family

ID=40568471

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/000186 WO2009147476A1 (en) 2008-06-02 2009-01-29 Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation

Country Status (1)

Country Link
WO (1) WO2009147476A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9018214B2 (en) 2011-04-21 2015-04-28 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9617283B2 (en) 2012-10-19 2017-04-11 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9617248B2 (en) 2012-10-19 2017-04-11 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9663512B2 (en) 2012-10-19 2017-05-30 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
US9783538B2 (en) 2013-12-20 2017-10-10 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9783546B2 (en) 2014-07-22 2017-10-10 Glaxosmithkline Intellectual Property Development Limited Compounds
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436333A2 (en) * 1990-01-05 1991-07-10 Pfizer Inc. Azaoxindole derivatives
WO2004089940A1 (en) * 2003-04-11 2004-10-21 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2004094416A1 (en) * 2003-04-24 2004-11-04 Elbion Ag 7-azaindoles and use thereof as therapeutic agents
WO2005090353A1 (en) * 2004-03-16 2005-09-29 Glaxo Group Limited PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436333A2 (en) * 1990-01-05 1991-07-10 Pfizer Inc. Azaoxindole derivatives
WO2004089940A1 (en) * 2003-04-11 2004-10-21 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2004094416A1 (en) * 2003-04-24 2004-11-04 Elbion Ag 7-azaindoles and use thereof as therapeutic agents
WO2005090353A1 (en) * 2004-03-16 2005-09-29 Glaxo Group Limited PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DALTON TRANSACTION, vol. 9, 2003, pages 1754 - 1758 *
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002525911, Database accession no. BRN:126585 *
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002525912, Database accession no. BRN:365494 *
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002525913, Database accession no. BRN:15023 *
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002525914, Database accession no. BRN:9504260 *
DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002525915, Database accession no. BRN:8509746 *
JOURNAL OF MEDICINAL CHEMISTRY, vol. 42, no. 23, 1999, pages 4853 - 4860 *
JOURNAL OF ORGANIC CHEMISTRY, vol. 19, 1954, pages 1127 - 1129 *
JOURNAL OF ORGANIC CHEMISTRY, vol. 21, 1956, pages 183 - 188 *
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 80, 1958, pages 2182 - 2184 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11866428B2 (en) 2011-04-21 2024-01-09 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9676768B2 (en) 2011-04-21 2017-06-13 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9018214B2 (en) 2011-04-21 2015-04-28 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9617283B2 (en) 2012-10-19 2017-04-11 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9617248B2 (en) 2012-10-19 2017-04-11 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9663512B2 (en) 2012-10-19 2017-05-30 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US11225476B2 (en) 2013-12-20 2022-01-18 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US10618895B2 (en) 2013-12-20 2020-04-14 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9783538B2 (en) 2013-12-20 2017-10-10 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US11643410B2 (en) 2013-12-20 2023-05-09 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
US9783546B2 (en) 2014-07-22 2017-10-10 Glaxosmithkline Intellectual Property Development Limited Compounds
US10125141B2 (en) 2014-07-22 2018-11-13 Glaxosmithkline Intellectual Property Development Limited Compounds
US10428078B2 (en) 2014-07-22 2019-10-01 Glaxosmithkline Intellectual Property Development Limited Compounds
US11999746B2 (en) 2014-07-22 2024-06-04 Glaxosmithkline Intellectual Property Development Limited Compounds
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas

Similar Documents

Publication Publication Date Title
WO2009147476A1 (en) Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation
JP6880127B2 (en) Synthesis of polycyclic carbamoylpyridone compounds
AU2009232017B2 (en) 1-heterocyclyl-1,5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as PDE9A modulators
EP3572416B1 (en) Diaryl macrocycles as modulators of protein kinases
EP1987030B1 (en) 3 -deazapurine derivatives as tlr7 modulators
EP2802577B1 (en) Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
AU2004215481B2 (en) Pyrazolo(1,5-A)pyrimidine derivatives
EP2464647B1 (en) Azaindazoles as btk kinase modulators and use thereof
EP2778156B1 (en) Phenoxypyridinylamide derivatives and their use in the treatment of PDE4 mediated disease states
PL219736B1 (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
BR112019012927A2 (en) COMPOUND, USE OF A COMPOUND, COMBINATION OF A COMPOUND, PHARMACEUTICAL COMPOSITION AND DEVICE
BRPI0716804A2 (en) DIBENZOFURAN DERIVATIVES AS PDE-4 AND PDE-10 INHIBITORS
RU2677697C1 (en) Triazolopyridine derivatives as modulators of tnf activity
WO2014074657A1 (en) Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators
EP1585735A1 (en) Hydroxamid acid derivatives as histone deacetylase (hdac) inhibitors
JP2013505295A (en) Compound that selectively modulates CB2 receptor
WO2022193499A1 (en) Amino heteroaryl compounds and compositions
KR20210136995A (en) Bruton's Tyrosine Kinase Inhibitors
WO2018015818A2 (en) Therapeutic inhibitory compounds
EP1590335A2 (en) Process for preparing pyrrolotriazine kinase inhibitors
WO2009115874A2 (en) Novel heterocyclic compounds, pharmaceutical compositions containing them and processes for their preparation
JP2020528440A (en) Improved process for preparing aminopyrimidine derivatives
EP2146983A1 (en) Pyrazoles useful in the treatment of inflammation
CA2810659A1 (en) Quinoxaline compound
WO2022063128A1 (en) Aromatic ring or arylheterocyclic pyridone compound, pharmaceutical compositions, and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09757831

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09757831

Country of ref document: EP

Kind code of ref document: A1